These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28372634)

  • 1. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis
.
    Messori A; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):517-520. PubMed ID: 28372634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
    Chadwick L; Zhao S; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept for the treatment of rheumatoid arthritis.
    Zhao S; Mysler E; Moots RJ
    Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept biosimilar SB-4.
    Pelechas E; Drosos AA
    Expert Opin Biol Ther; 2019 Mar; 19(3):173-179. PubMed ID: 30616405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in rheumatology: out of the laboratory and into practice.
    Rutherford AI; Galloway JB
    Expert Rev Clin Immunol; 2016 Jul; 12(7):697-9. PubMed ID: 27195989
    [No Abstract]   [Full Text] [Related]  

  • 12. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GP2015 as a promising therapy for rheumatoid arthritis.
    Fitton J; Giollo A; Buch MH
    Expert Opin Biol Ther; 2018 Apr; 18(4):477-481. PubMed ID: 29558865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of etanercept biosimilars in comparison with etanercept in patients with rheumatoid arthritis who have insufficient response to methotrexate: A network meta-analysis.
    Lee YH; Song GG
    Int J Clin Pharmacol Ther; 2021 Dec; 59(12):760-767. PubMed ID: 34622769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis as a tool for improving the effectiveness assessment of biosimilars based on both direct and indirect evidence: application to infliximab in rheumatoid arthritis.
    Messori A; Trippoli S; Marinai C
    Eur J Clin Pharmacol; 2017 Apr; 73(4):513-514. PubMed ID: 27966035
    [No Abstract]   [Full Text] [Related]  

  • 17. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
    Mengato D; Messori A
    Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
    [No Abstract]   [Full Text] [Related]  

  • 18. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
    Mengato D; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of biosimilars for rheumatoid arthritis.
    Conran CA; Moreland LW
    Curr Opin Pharmacol; 2022 Jun; 64():102234. PubMed ID: 35552095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.
    Dormuth CR; Fisher A; Carney G
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):796-802. PubMed ID: 31914214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.